NovoCure (NASDAQ:NVCR) COO Mukund Paravasthu Sells 43,246 Shares

NovoCure Limited (NASDAQ:NVCR) COO Mukund Paravasthu sold 43,246 shares of the business’s stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $13.77, for a total value of $595,497.42. Following the transaction, the chief operating officer owned 72,832 shares in the company, valued at $1,002,896.64. The trade was a 37.26% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Mukund Paravasthu also recently made the following trade(s):

• On Wednesday, March 4th, Mukund Paravasthu sold 5,377 shares of NovoCure stock. The stock was sold at an average price of $13.31, for a total transaction of $71,567.87.

NovoCure Price Performance

NVCR stock traded down $0.90 during trading on Friday, reaching $13.33. 347,451 shares of the company were exchanged, compared to its average volume of 2,188,230. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.50 and a current ratio of 2.90. The stock’s 50 day moving average price is $12.75 and its 200 day moving average price is $12.71. NovoCure Limited has a 52-week low of $9.82 and a 52-week high of $21.55. The company has a market cap of $1.52 billion, a P/E ratio of -10.89 and a beta of 0.71.

NovoCure (NASDAQ:NVCR) last posted its earnings results on Thursday, February 26th. The medical equipment provider reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.19. NovoCure had a negative return on equity of 39.11% and a negative net margin of 20.79%.The company had revenue of $174.35 million for the quarter, compared to analyst estimates of $174.40 million. During the same quarter in the prior year, the company earned ($0.61) earnings per share. NovoCure’s revenue was up 8.2% compared to the same quarter last year. As a group, analysts predict that NovoCure Limited will post -1.3 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on NVCR shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NovoCure in a research report on Thursday, January 22nd. HC Wainwright raised their price target on NovoCure from $47.00 to $49.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Wedbush restated a “neutral” rating and issued a $18.00 price target on shares of NovoCure in a report on Thursday, January 15th. Finally, Evercore set a $20.00 price objective on shares of NovoCure in a report on Monday, January 5th. Three investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, NovoCure currently has a consensus rating of “Hold” and an average price target of $26.93.

NovoCure News Summary

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: Quarterly results showed an EPS beat and revenue growth (year-over-year revenue +8.2%), which supports fundamentals and was cited by analysts when updating models. MarketBeat NVCR coverage
• Positive Sentiment: Some sell‑side firms remain constructive: HC Wainwright raised its price target and several analysts maintain Buy ratings or higher targets, providing upside cases versus the current share price. Analyst notes (MarketBeat)
• Neutral Sentiment: Brokerages’ consensus rating is “Hold,” indicating limited near‑term conviction for a re‑rating; consensus target remains well above the current price, which creates a mixed signal for investors. NovoCure receives average “Hold” rating
• Neutral Sentiment: Institutional ownership is high (reported ~84.6%), which can reduce free‑float volatility but also means insider moves may attract outsized attention. Institutional holdings (MarketBeat)
• Negative Sentiment: Chairman William F. Doyle sold a large block (71,887 shares, ≈$933k at ~$12.98), trimming his stake by ~18% — a sizable single insider sale that the market interprets as a negative signal. SEC filing: Doyle sale
• Negative Sentiment: Multiple senior executives (COO, CEO, CFO and other insiders) executed notable sales over the same period — a pattern that amplifies negative sentiment and likely pressured the stock intraday. Aggregated filings and coverage of these insider transactions are available. Insider trades summary (MarketBeat)

Hedge Funds Weigh In On NovoCure

A number of institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in shares of NovoCure by 4.8% in the 4th quarter. Vanguard Group Inc. now owns 10,958,209 shares of the medical equipment provider’s stock valued at $141,690,000 after purchasing an additional 502,368 shares in the last quarter. Soleus Capital Management L.P. increased its holdings in NovoCure by 25.0% in the second quarter. Soleus Capital Management L.P. now owns 6,904,302 shares of the medical equipment provider’s stock valued at $122,897,000 after buying an additional 1,382,888 shares during the last quarter. Morgan Stanley raised its stake in NovoCure by 453.4% during the fourth quarter. Morgan Stanley now owns 5,069,895 shares of the medical equipment provider’s stock valued at $65,554,000 after buying an additional 4,153,741 shares in the last quarter. Balyasny Asset Management L.P. lifted its holdings in NovoCure by 38.8% during the 2nd quarter. Balyasny Asset Management L.P. now owns 2,270,076 shares of the medical equipment provider’s stock worth $40,407,000 after buying an additional 634,925 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in NovoCure by 29.4% during the 4th quarter. Renaissance Technologies LLC now owns 1,387,754 shares of the medical equipment provider’s stock worth $17,944,000 after buying an additional 314,900 shares during the last quarter. Institutional investors and hedge funds own 84.61% of the company’s stock.

NovoCure Company Profile

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.